Altogether, developing a non-cell permeable CDA inhibitor or a method to remove plasma CDA may be of immediate use in cancer patients not responding to cytidine analogues and, also perhaps to improve the therapeutic index of DHODH inhibitors. The gene discussed is CDA; the disease is cancer.